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Introduction
Amniotic fluid (AF) is a liquid that fills the 
amniotic cavity which has defense and nutritional 
functions in fetal development. The volume and 
composition of AF can be changed according to 
the age of the pregnancy. At the beginning of fetal 
development, AF is produced by the maternal plasma. 
In 8 weeks of gestation, the kidneys begin to produce 
fluids that significantly add AF. Recent findings on stem 
cell sources show that AF contains novel stem cells 
(AFS = AF stem cell), characterized by c-kit expression 
(stem cell factor receptor), illustrating that AFS can be 
used in regenerative medicine [1].
There is a heterogeneous population of the 
three developmental plates in AF. In this tissue, cells are 
found from the inner layer of the amniotic membrane 
(AM) or from developing fetal cells. Cells in AF are 
grouped based on morphology, growth, and biochemical 
characteristics. Epithelioid cells (E type) are cuboid to 
columnar cells that originate from the skin and urine 
of the fetus, AF cells (AF type) from fetal membranes 
(AF type), and fibroblastic (F type) cells originating from 
connective tissue fibrous. Immunophenotypes showing 
AF stem cells are dominated by mesenchymal stem cells 
(MSCs) known as AF-derived MSCs (AF-MSCs) [2].
MSCs are multipotent and self-renewal cells. In 
the study of Asl et al., comparison between mesenchymal 
cells originating from human amnion and mesenchymal 
cells originating from adipose cells. In this study, a higher 
proliferative power was obtained in mesenchymal cells 
originating from human amnion compared to those 
derived from human adipose cells. In the study of Gaafar 
et al., a comparison is made between MSC on amnion, 
endometrium, and ovary. All three have almost the same 
molecular structure, but MSC derived from AF has a 
lower immune response and higher transplant success 
in xenogenetic hosts [3], [4].
Human term AF can be an ideal alternative 
as a source of MScs, originating from the neonate. 
Preclinical studies of the second- and third-trimester 
amnion fluid cells confirmed the number of potential 
donors from this wasted material. Human AF stem cells 
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(hAFSCs) can be obtained noninvasively. hAFSCs have 
proliferative rates, induce immunological tolerance, 
describe embryonic stem cell (ESC) properties, and 
can differentiate into three developmental plates 
and several cell lineages, such as adipocytes, 
osteoblasts, chondrocytes, kidney cells, hepatocytes, 
and cardiomyocytes. This characteristic suggests that 
hAFSC can be an ideal source of application for stem 
cell therapy [5], [6].
AF has an essential function in fetal 
development, nutrition, and defense. The volume and 
composition of AF already changed according to the 
age of the pregnancy. AF is also used for screening of 
genetic disorders, embryos, infections, and congenital 
disorders. Besides that, AF has some variety of stem 
cells from developing fetuses which can be a source of 
stem cell development [1], [7].
AF is a promising source of stem cells. AF is 
found in many types of stem cells, from primordial cells 
that are pluripotent to specific organ progenitor cells 
and adult cells. In addition, hematopoietic progenitor 
cells and genetic markers of specific tissues such as the 
brain, heart, and pancreas were also found. Recently, 
AF has become a source of MSCs for therapeutic 
therapy with minimal risk of tumor formation [1], [8].
Tsai et al. (2004) in their study succeeded in 
isolating AF-MSC in the second trimester of pregnancy. 
Isolation was obtained without disturbing the karyotype 
process of the fetus using the novel two-stage culture 
protocol method. Cells obtained from this process can 
develop into several cell types in vitro [9].
Materials and Methods
This is an experimental research  with post-test-
onlly control group design. The sample used in this study 
amounted to three patients. The study was conducted in 
the biomedical laboratory and the laboratory of Institute 
of Medical Education and Research in Indonesia, 
Faculty of Medicine, University of Indonesia.
Inclusion and exclusion criteria
A term gestational age (37–41 weeks), the 
patient does not have other comorbid diseases, AF is 
normal, in healthy AF, cells develop well until passage 
3 and there is no contamination during the culture 
process and exclusion criteria are failed to breed cells.
Preparation of AF-MSCs
There AF samples from healthy human donors 
were collected during full-term C-sections and kept 
at 4°C until processed. In general, the time between 
collection and processing was kept as short as possible 
to minimize cell death. First, AF was washed with 
phosphate-buffered saline (PBS) and centrifuged at 
300 × g for 5 min. The supernatant was discarded, and 
the pellet washed again with PBS. Thereafter, the cell 
solution was incubated at 4°C for 20 min and centrifuged 
again. This procedure was repeated until the pellet had 
a clear color. Afterward, the cells were cultured in Chang 
C Medium containing 88% α-mem with 10% fetal bovine 
serum, 1% Glutamax, 1% penicillin/streptomycin, 10% 
Chang B Basal Medium, and 2% Chang C supplement 
at 37°C and 5% CO2 [10].
Colony-forming unit-fibroblast (CFU-F) 
assays
After 11–14 days of cell culture, the number 
of CFU-F was assessed microscopically by calculating 
spindle-shaped colonies that clearly resembled 
fibroblasts and did not include colonies with rounded 
epithelioid morphology. Colonies containing ≥40 cells 
were counted [5]. The AF culture was carried out in the 
biomedical laboratory of Andalas University.
Flow cytometric analysis of AF-MSCs
The immunophenotyping of their independent 
AF preparations was done using the human MSC 
(hMSC) phenotyping kit which was done according to 
the manufacturer’s instruction. After harvesting, 2 × 105 
AF-MSCs were transferred into two test tubes. A 2 ml 
PBS was added to each tube and centrifuged at 300 × g 
for 5 min. The supernatant was discarded and the pellet 
resuspended in 100 ul PBS within the tubes. In one of 
the tubes, 0.5 ul of the MSC phenotyping cocktail and 
the other tube 0.5 ul of isotype control cocktail were 
added and vortexed. The MSC phenotyping cocktail 
contained fluorochrome-conjugated monoclonal 
antibodies CD73-APC, CD90-FITC, and CD105-PE. The 
isotype phenotyping cocktail contained fluorochrome-
conjugated antibodies that should not, especially, 
detect human antibodies and was, therefore, used as 
a negative control. The tubes were incubated at 4°C for 
10 min in the dark until flow cytometric analysis through 
BD FACSCanto was done [10].
Statistics
Data are presented in descriptive form and 
presented as a percentage.
Research ethics
This research has received ethical 
considerations and approval from the Research Ethics 
Committee Team of the Medical Faculty of Andalas 
University with registration number 015/KEP/FK/2019.
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Results
Morphology from AF-MSCs
From this study, we succeeded in getting 8 
million cells which will be used for research on pelvic 
organ prolapse therapy using AF-MSCs. The stem cell 
isolation totally takes 6 weeks. We got 2 million stem 
cell cells in one flask.
Figure 1 shows that cell of AF-MSC resembles 
fibroblast cells. Haasters et al., (2009), hMSCs are a 
disorders. Besides that, AF has some variety of stem 
cells from developing fetuses which can be a source 
of stem cell development. Recent findings on stem cell 
sources show that AF contains novel stem cells (AFS = 
AF stem cell), characterized by c-kit expression (stem 
cell factor receptor), illustrating that AFS can be used 
in regenerative medicine. AF is generally obtained from 
diagnostic actions of amniocentesis and therapeutic 
amnioreduction. Although the chemical and cellular 
composition varies from each gestational age, MSC 
can be isolated at any time during pregnancy. There 
are several isolation techniques of AF-MSCs that are 
commonly used, namely, multiple wells and coverslips. 
From this study, we succeeded in getting 8 million cells 
which will be used for research on pelvic organ prolapse 
therapy using AF-MSCs. The stem cell isolation totally 
takes 6 weeks. We got 2 million stem cell cells in one 
flask.
The MSCs, which are derived from the 
mesoderm, are considered as a readily available 
source for tissue engineering. They have multipotent 
differentiation capacity and can be differentiated into 
various cell types. Many studies have demonstrated that 
the MSCs identified from the AM (AM-MSCs) and AF 
(AF-MSCs) are shown advantages for many reasons, 
including the possibility of non-invasive isolation, 
multipotency, self-renewal, low immunogenicity, anti-
inflammatory, and non-tumorigenicity properties, and 
minimal ethical problem. The AF-MSCs and AM-MSCs 
may be appropriate sources of MSCs for regenerative 
medicine, as an alternative to ESCs. Recently, 
regenerative treatments such as tissue engineering 
and cell transplantation have shown potential in clinical 
applications for degenerative diseases [12].
Human AF cells are immune privileged with low 
immunogenicity and anti-inflammatory properties. They 
are able to self-renew, are highly proliferative, and have 
a broad differentiation potential, making them amenable 
Figure 1: Morphology of amniotic fluid-mesenchymal stem cells
heterogeneous cell population, which are reflected in 
varying morphological and biological properties. Three 
subpopulations with intrinsic characteristics can be 
distinguished as follows: Small rapidly self-renewing 
cells, spindle-shaped cells, and large, flattened cells [11].
Flow cytometry analysis of AF-MSCs
Figure 2 shows that marker CD used in this 
research for AF-MSCs as follows: CD90, CD73, and 
CD105.
Discussion
AF has an essential function in fetal 
development, nutrition, and defense. The volume and 
composition of AF already changed according to the 
age of the pregnancy. AF is also used for screening of 
genetic disorders, embryos, infections, and congenital 
Figure 2: Flow cytometry amniotic fluid-mesenchymal stem cells
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for cell-based therapies. AF is routinely obtained through 
amniocentesis and contains heterogeneous populations 
of fetal-derived progenitor cells including MSCs. These 
AF-MSCs showed typical MSC characteristics such as 
morphology, in vitro differentiation potential, surface 
marker expression, and secreted factors [10].
Amniotic stem cells (ASCs) can be extracted 
from the amniotic sac through the amniocentesis 
process, where this process can be carried out without 
injuring the developing fetus. This is very important 
to emphasize because of the negative stigma toward 
embryonically derived stem cells. Another study showed 
isolation of AF through cesarean section labor using a 
catheter [5], [13].
AF and ASC have many advantages related 
to medical use. First, fluid and amniotic cells have 
immunological features which mean that they do not 
cause a reaction even among donors and recipients 
who are totally unrelated. Second, the AF contains 
more stem cells than the adult bone marrow. ASC is like 
a hybrid between ESCs and adult stem cells in terms 
of plasticity and differentiation ability. Third, the AF 
contains hyaluronic acid, which helps lubrication and 
can be used in the treatment of joints. Fourth, the AF 
contains a complete complement of growth factors that 
stimulate stem cells to differentiate into many cell types. 
Then, AF is naturally antimicrobial and can prevent and 
eliminate potential infectious agents [13].
In the comparison of AFMSCs with BMSC 
according to the same growth time (day 15), amniotic 
cells showed more cells than stem cells originating 
from the ACS bone marrow. It normally larger and more 
numerous than stem cells originating from the bone 
marrow, indicates AFMSCs grow and differentiates 
faster. This is needed for treatment because it shortens 
the patient’s healing time and can also reduce the 
amount of treatment needed [13]. AF is generally 
obtained from diagnostic actions of amniocentesis and 
therapeutic amnion reduction. Although the chemical 
and cellular composition varies from each gestational 
age, MSC can be isolated at any time during pregnancy. 
There are several isolation techniques of AF-MSCs 
that are commonly used, namely, multiple wells and 
coverslips [14].
In the coverslips method, mechanical 
separation is obtained by placing a pellet on the cover 
glass of the object distributed on a 10 cm collagen-
coated plate with a cell density of 2–3 million cells in 
150 cm2. After 48 h, the cover glass of the object was 
observed and selected cells containing mesenchymal 
cells were placed on a 30 cm2 culture plate (containing 
the 20 mesenchymal medium). The medium is replaced 
every day following the steps of the multiple wells 
method [14].
MSC develops according to the growing 
medium. In analyzing surface antigens with flow 
cytometry, polymerase chain reaction, and staining 
of immunocytochemistry, AF-MSCs were expressed 
the same mesenchymal markers from other sources. 
In several studies, AF-MSCs express mesenchymal 
markers such as CD90, CD73 (SH3, SH), CD105 
(SH2), CD29, CD166, CD49e, CD58, and CD44 (MHC 
Class I). These cells also express HLA-ABC antigens, 
CD 34, and CD 45 which are hematopoietic markers 
and endothelial CD31 markers. There is no expression 
of CD10, CD11b, CD14, CD34, CD117, EMA, and 
HLA-DR, DP, and DQ antigens. Most of AF-MSCs 
have pluripotent properties which are characterized by 
the discovery of octamer-binding protein 3/4 (Oct-3/4), 
transcription factors Nanog (Nanog), and stage-
specific embryonic antigen 4 (SSEA-4) on RT-PCR 
examination [2], [9], [15].
Along with the development of stem cell 
research, the standard criteria for MSC are needed. 
The international study for cellular therapy recommends 
the minimum criteria for determining of MSC. These 
criteria include derived from the fetus, ≤1% maternal 
contamination, MSC has plastic adherence properties, 
can develop to form CFU-F, having specific antigen 
expression. The population of MSC can express 
CD105 (Endoglin), CD73, and CD 90 (Thy-1) of ≥95% 
as measured by cytometry flow. There was a lack of 
CD45, CD34, CD14 or CD11b, CD79α or CD19, and 
HLA Class II expressions (≤2% positive) and MSC 
must be multipotent differentiated into osteoblasts, 
adipocytes, and chondroblasts under in vitro standard 
conditions [16], [17].
Conclusion
The time needed for differentiation of AF-MSCs 
is 6 weeks and AF-MSCs express mesenchymal 
markers such as CD90, CD73 (SH3, SH), and CD105 
(SH2) and these cells also express HLA antigens – 
ABC, CD 34, and CD 45 which are hematopoietic 
markers and endothelial CD31 markers.
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